ArticleFrontiers in cell and developmental biology2025
Detection of circulating hybrid cells and circulating tumor cells in cerebrospinal fluid for leptomeningeal metastasis diagnosis and therapeutic prediction.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Leptomeningeal metastasis (LM) represents a serious complication of advanced malignancies with poor prognosis. Conventional diagnostic approaches, such as MRI and cerebrospinal fluid (CSF) cytology lack sufficient sensitivity-particularly in early-stage disease or when imaging modalities are inconclusive. This study explores the diagnostic utility of circulating tumor cells (CTCs) and circulating hybrid cells (CHCs) in CSF for LM detection. Methods: A cascaded filter deterministic lateral displacement microfluidic chip was utilized to enrich CTCs and CHCs from the CSF of 27 patients with LM and 22 individuals with non-neoplastic neurological conditions. Identification of CSF-derived CTCs and CHCs was based on immunofluorescence staining combined with characteristic neoplastic morphology. Results: The detection frequency and absolute counts of CTCs and CHCs were markedly elevated in LM patients compared to non-LM controls (p < 0.0001). A positive correlation was observed between CTC and CHC levels (rs = 0.8406, p < 0.0001). ROC analysis revealed robust diagnostic performance, with AUC values of 0.8727 for CTCs, 0.8600 for CHCs, and 0.9545 for CK-positive cells (a composite of CTCs and CHCs). Importantly, in two LM cases where MRI and cytology failed to provide diagnostic confirmation, CSF-CTC and CHC analyses successfully identified significant cell counts. Conclusion: CSF-CTCs and CHCs represent promising biomarkers for LM diagnosis and therapeutic prediction with high sensitivity and specificity, complementing traditional MRI and cytology diagnostic approaches. These findings highlight their potential clinical utility and underscore the need for further studies to explore CHC formation mechanisms and their implications in LM pathogenesis and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.